Results 221 to 230 of about 25,109 (253)

Patritumab deruxtecan (HER3-DXd) in resistant EGFR -mutated ( EGFR m) advanced non-small cell lung cancer (NSCLC) after a third-generation EGFR TKI: The phase 3 HERTHENA-Lung02 study.

Journal of Clinical Oncology
8506 Background: After disease progression on a 3rd-gen (3G) EGFR TKI for advanced EGFR m NSCLC, available therapies provide limited efficacy.
Tony S. K. Mok, H. Yu, Sun Min Lim, I. Okamoto, M. Pérol, S. Novello, C. Dooms, Jong-Mu Sun, S. Kao, P. Jänne, Martin Reck, Conor E Steuer, M. Nishio, Yi-Long Wu, Xiaofang Li, R. Fougeray, R. Kudchadkar, Jianyu Wu, S. Esker, A. Passaro   +19 more
semanticscholar   +1 more source

Abstract LB-B11: Assessment of HER3 status during lapatinib treatment in HER3-positive breast cancer using 89Zr-anti-HER3 mAb

Molecular Cancer Therapeutics, 2015
Abstract Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with the HER-targeting tyrosine kinase inhibitor lapatinib can lead to a rapid compensatory increase in expression, signaling activity and relocalization of HER3 to the plasma membrane, which may attenuate the response to lapatinib.
Arjan Kol, Martin Pool, Steven de Jong, Elisabeth GE de Vries, Marjolijn N. Lub-de Hooge, Anton GT Terwisscha van Scheltinga   +5 more
openaire   +1 more source

Abstract 3306: Targeting HER3 receptor positive cancers with a novel anti-HER3 antibody radioconjugate (ARC)

Cancer Research, 2022
Abstract Background: HER3 overexpression is reported to be associated with poor survival in breast, ovarian, lung, gastric and prostate cancer. In addition, upregulation of HER3 in response to HER1 or HER2 targeted therapies, is implicated in the acquired resistance against these therapies.
Denis Beckford-Vera, Jason Li, Megan McCloskey, Caroline Jennings, Amanda Chin, Qing Liang, Jesse Hwang, Monideepa Roy, Mary Chen, Helen Kotanides   +9 more
openaire   +1 more source

Keeping it in the family: HER3 as a target in brain metastases.

Clinical Cancer Research, 2023
In 180 patients with metastatic breast cancer and NSCLC, HER3 expression was found in >70% of brain metastases (BM). HER3-targeting antibody-drug conjugates have demonstrated efficacy in HER3-expressing metastatic breast cancer and NSCLC.
S. Kabraji, N. Lin
semanticscholar   +1 more source

LRG1 promotes metastatic colorectal cancer growth through HER3 signaling.

Gastroenterology
BACKGROUND AND AIMS Therapy failure in patients with metastatic colorectal cancer (mCRC, ∼80% occur in the liver) remains an overarching challenge.
Moeez Rathore, K. Curry, Wei Huang, Michel’le Wright, Daniel Martin, Jiyeon Baek, Derek J Taylor, Masaru Miyagi, Wen Tang, Hao Feng, Yamu Li, Zhenghe Wang, Hallie Graor, Joseph E. Willis, Elizabeth Bryson, Christina S. Boutros, Omkar Desai, B. Islam, Lee M. Elis, Stephen E Moss, Jordan M Winter, John Greenwood, Rui Wang   +22 more
semanticscholar   +1 more source

Abstract LB-306: U3-1287 (AMG 888), a fully human anti-HER3 mAb, inhibits HER3 activation and induces HER3 internalization and degradation

Cancer Research, 2010
Abstract Background: Understanding the mechanism of action (MOA) of novel therapeutic agents is instrumental for their recommended use in the clinic. U3-1287 (AMG 888) is a novel, fully human mAb that targets HER3, a member of the EGFR family involved in tumor growth and resistance to anti-HER inhibitors.
Thore Hettmann, Matthias Schneider, Selam Ogbagabriel, Jiansong Xie, Gloria Juan, Susanne Hartmann, Robert Radinsky, Daniel J. Freeman   +7 more
openaire   +1 more source

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.

Journal of Clinical Oncology, 2022
9017 Background: Patients (pts) with advanced NSCLC without EGFR-activating mutations ( EGFRm) have limited treatment options after failure of molecularly targeted therapies or platinum-based chemotherapy (PBC) with or without immunotherapy (IO).
C. Steuer, H. Hayashi, Wu-Chou Su, M. Nishio, M. Johnson, Dong-Wan Kim, M. Koczywas, E. Felip, K. Gold, H. Murakami, C. Baik, Sang-We Kim, E. Smit, M. Gigantone, Ben Kim, P. Fan, Zhenhao Qi, Elaine Y Wu, D. Sternberg, P. Janne   +19 more
semanticscholar   +1 more source

The Therapeutic Significance of HER3 in Non-small Cell Lung Cancer (NSCLC): A Review Study.

Current Medicinal Chemistry
HER3 (Human Epidermal Growth Factor Receptor 3) is frequently overexpressed in various cancers, including non-small cell lung cancer (NSCLC), with a prevalence of 83% in primary tumors.
Amelia Trinder, Ke Ding, Jinwei Zhang
semanticscholar   +1 more source

HER3 as a Therapeutic Target in Cancer

BioDrugs, 2016
Targeting members of the human epidermal growth factor receptor family, especially EGFR and HER2, has been an established strategy for the treatment of tumors with abnormally activated receptors due to overexpression, mutation, ligand-dependent receptor dimerization and ligand-independent activation.
Niki Karachaliou, Chiara Lazzari, Alberto Verlicchi, Aaron E. Sosa, Rafael Rosell   +4 more
openaire   +2 more sources